Tirzepatide vs Retatrutide: What the Research Shows
Tirzepatide and Retatrutide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Tirzepatide if…
- you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[16]
- you want large randomized weight-loss data (the SURMOUNT program): Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) with tirzepatide versus -3.1% with placebo.[15]
- you are tested in sport and want to avoid a WADA-prohibited substance: Retatrutide is prohibited by WADA at all times (check tirzepatide's own status separately)[6]
Consider Retatrutide if…
- you are weighing an investigational option (no FDA-approved product yet): the TRIUMPH trial reported mean weight change of -25.0% with the 12-mg dose versus -3.9% with placebo[1]
- you want to know where approval stands: Lilly states it plans to submit a Biologics License Application to the FDA, a submission plan and not an approval[17]
Spec comparison
Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Tirzepatide | Retatrutide |
|---|---|---|
| Class | GLP-1 / GIP dual agonist | GLP-1 / GIP / glucagon triple agonist |
| Also called | tirz, tirze, Mounjaro, Zepbound | reta, GLP-3, LY3437943 |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | FDA approved (Mounjaro, Zepbound) | Investigational · phase 3 |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. |
| Half-life | approximately 5 dayssubcutaneous · FDA label (Mounjaro) | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 |
| Human studies we summarised | 24 human (22 randomized or controlled) of 30 summarised | 11 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg | 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Tirzepatide and Retatrutide together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 108 results, 2 Oct 2026).
There is no trial of the two against each other
This site's evidence files hold no trial that randomizes people to tirzepatide or retatrutide, so the comparison sets one drug's trials beside the other's. The retatrutide abstract lists Eli Lilly and Company as funder.[18]
Their pharmacology differs by one receptor. Retatrutide is a single peptide that acts at glucagon, GIP and GLP-1 receptors, whereas tirzepatide is a GIP and GLP-1 receptor agonist.[11]
Tirzepatide's SURMOUNT-2 trial, in adults with obesity and type 2 diabetes, read out body-weight change at week 72.[19]
Retatrutide's TRIUMPH-2, in the same two conditions, read out weight at week 80, so the end-of-trial percentages are not like for like.[18]
Retatrutide's TRIUMPH-2 primary comparison was weight change at week 80 for the 9 mg and 12 mg doses against placebo, with 4 mg a key secondary endpoint.[18]
Beyond weight: what each drug was tested on
Tirzepatide has two phase 3 trials in adults with moderate-to-severe obstructive sleep apnea and obesity.[20]
Retatrutide's TRIUMPH-1 trial nests sleep apnea and knee osteoarthritis as subgroups of an obesity trial, covering 243 participants with sleep apnea and 574 with knee osteoarthritis, rather than separate trials.[1]
Tirzepatide's label starts at 2.5 mg once weekly for 4 weeks and then steps up, so its dosing schedule is fixed by an approved label.[16]
Retatrutide's phase 2 obesity trial ran 48 weeks, and at its top dose weight fell -24.2% against -2.1% on placebo.[21]
Safety signals and half-life as reported
In the retatrutide diabetes-and-obesity trial, diarrhoea affected 34% of the 12 mg group versus 13% of placebo, and nausea 28% versus 8%.[18]
The same trial reported hypotension and dysesthesia more often on retatrutide than on placebo.[18]
Tirzepatide's SURMOUNT-1 abstract reports that adverse events caused discontinuation in 7.1% on 10 mg, versus 2.6% on placebo.[15]
Retatrutide's half-life was approximately 6 days in its phase 1b diabetes trial.[11]
Tirzepatide's label gives an elimination half-life of approximately 5 days and says this enables once-weekly dosing.[7]
Retatrutide has no FDA record: the Drugs@FDA search for the active ingredient returned no matches.[22]
Common questions
Is retatrutide stronger than tirzepatide?
No trial pits them directly. Retatrutide's phase 2 obesity trial reported -24.2% weight change at 48 weeks on 12 mg against -2.1% on placebo; the tirzepatide trials ran for different lengths, so the figures are not directly comparable.[21]
Is retatrutide available like Zepbound or Mounjaro?
No. Zepbound and Mounjaro are FDA-approved tirzepatide products, while retatrutide is investigational and has no Drugs@FDA record.[22]
What is the difference in how they work?
Retatrutide adds glucagon receptor activity to the GIP and GLP-1 activity that tirzepatide also has.[11]
Do both need weekly injections?
Retatrutide's phase 1b abstract puts its half-life at approximately 6 days.[11]
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 6World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 7These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 8Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 9Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 10Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 11LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 12Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 13Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 14PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 16ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 17Official web pageOfficial web page · web page
- 18Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
- 19Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet (London, England) · 2023PMID 37385275Accessed 2 Oct 2026
- 20Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.The New England journal of medicine · 2024PMID 38912654Accessed 2 Oct 2026
- 21Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 22Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.